| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/22/2011 | US20110229411 Use of p2x7 pathway for assessing the sensitivity of a subject to a cancer treatment |
| 09/22/2011 | US20110229407 Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof |
| 09/22/2011 | US20110229406 Material and methods for treating or preventing HER-3 associated diseases |
| 09/22/2011 | US20110226650 Antibody formulation |
| 09/22/2011 | CA2793657A1 Myeloid derived suppressor cell inhibiting agents |
| 09/22/2011 | CA2793604A1 Lipid vesicle compositions and methods of use |
| 09/22/2011 | CA2793458A1 System and method of preparing and storing activated mature dendritic cells |
| 09/22/2011 | CA2793389A1 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers |
| 09/22/2011 | CA2793087A1 Peptides, conjugates and method for increasing immunogenicity of a vaccine |
| 09/22/2011 | CA2792956A1 Bacterial vaccine components from staphylococcus aureus and uses thereof |
| 09/22/2011 | CA2790699A1 Anti-nerve growth factor (ngf) antibody compositions |
| 09/22/2011 | CA2789857A1 Novel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| 09/22/2011 | CA2786940A1 Tumor vaccination involving a humoral immune response against self-proteins |
| 09/21/2011 | EP2366718A2 Ligand |
| 09/21/2011 | EP2366716A2 Combinatorial therapy involving alpha5beta1 antagonists |
| 09/21/2011 | EP2366715A2 Rankl Antibody-PTH/PTHRP Chimeric Molecules |
| 09/21/2011 | EP2366713A2 Polypeptide variants with altered effector function |
| 09/21/2011 | EP2366711A2 Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer |
| 09/21/2011 | EP2366709A1 Tumor vaccination involving a humoral immune response against self-proteins |
| 09/21/2011 | EP2366708A1 Canine astrovirus AstV strain Bari/08 identified in dogs with gastro-enteritis |
| 09/21/2011 | EP2366707A1 Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
| 09/21/2011 | EP2366706A1 Regeneration of endogenous myocardial tissue by induction of neovascularization |
| 09/21/2011 | EP2366406A1 Method for treating psoriasis |
| 09/21/2011 | EP2366405A2 IL-17 antagonistic antibodies |
| 09/21/2011 | EP2366404A2 Polysaccharide-protein conjugate vaccines |
| 09/21/2011 | EP2366403A2 Polysaccharide-protein conjugate vaccines |
| 09/21/2011 | EP2365987A1 Isoform specific anti-her4 antibodies |
| 09/21/2011 | EP2365827A1 Fully human influenza m2 specific antibodies |
| 09/21/2011 | EP2365826A1 Vaccine |
| 09/21/2011 | EP2365825A1 Cross-beta structures as carriers in vaccines |
| 09/21/2011 | EP2365824A1 Salmonella marker vaccine |
| 09/21/2011 | EP2365823A1 Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| 09/21/2011 | EP1888636B1 Method for the purification of antibodies |
| 09/21/2011 | EP1802339B1 Treating neoplasms with neurotoxin |
| 09/21/2011 | EP1651765B8 Novel photobacterium damselae nucleotide and amino acid sequences and uses thereof |
| 09/21/2011 | EP1597282B1 Antibody molecules having specificity for human il-1 beta |
| 09/21/2011 | EP1565493B1 Antibody for the thyrotropin receptor and uses thereof |
| 09/21/2011 | EP1519956B1 Epha2 monoclonal antibodies and methods of use thereof |
| 09/21/2011 | EP1507547B1 Peptides for regulation of urokinase (upa) and tissue type (tpa) plasminogen activator and method of optimizing therapeutic efficacy |
| 09/21/2011 | EP1487428B1 Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders |
| 09/21/2011 | EP1399556B1 Antigenic epitopes of factor viii, inhibitors directed against said epitopes and use thereof |
| 09/21/2011 | EP1385993B8 Method of detecting and treating tuberous sclerosis complex associated disorders |
| 09/21/2011 | EP1341546B1 Kyberdrug as autovaccines with immune-regulating effects |
| 09/21/2011 | EP1296998B1 Hcv variants |
| 09/21/2011 | EP1135408B1 Hbv core antigen particles with multiple immunogenic components attached via peptide ligands |
| 09/21/2011 | EP1073905B1 Methods of selecting internalizing antibodies |
| 09/21/2011 | EP1068357B1 Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
| 09/21/2011 | CN1972710B Methods and compositions comprising bacteriophage nanoparticles |
| 09/21/2011 | CN1468089B Microparticles for delivery of the heterologous nucleic acids |
| 09/21/2011 | CN102197051A Uses of IL-22, IL-17, and IL-1 family cytokines in autoimmune diseases |
| 09/21/2011 | CN102197050A Hepatitis c antibodies and uses thereof |
| 09/21/2011 | CN102196818A Combination vaccine with acellular pertussis |
| 09/21/2011 | CN102196817A Combination vaccine with whole cell pertussis |
| 09/21/2011 | CN102196816A Methods for determining the levels of TGF-beta in a composition |
| 09/21/2011 | CN102191211A Salmonellapullorum attenuated mutant strain deltaS6702(SpiA) and construction method thereof |
| 09/21/2011 | CN102191210A Salmonella pullorum attenuated mutant strain delta S6702 (MetE) and construction method thereof |
| 09/21/2011 | CN102190734A Tubercle bacillus fusion protein Mtb8.4-HspX, and preparation method and application thereof |
| 09/21/2011 | CN102190733A Tag-free tubercle bacillus fusion protein ESAT6-RpfE and preparation method and application thereof |
| 09/21/2011 | CN102190729A Anti-human CD80 bivalent dimer and application thereof |
| 09/21/2011 | CN102190728A Novel humanized anti-CD20 monoclonal antibody |
| 09/21/2011 | CN102190727A Monoclonal antibody, composition taking same as active ingredient, and application of monoclonal antibody |
| 09/21/2011 | CN102190726A Fab segment of human HIV antibody, and coding gene and application thereof |
| 09/21/2011 | CN102190725A Hand-foot-and-mouth disease resistant human immunoglobulin, and preparation and using methods and application thereof |
| 09/21/2011 | CN102188707A Application of IL-17 inhibitor in preparing medicament for treating influenza |
| 09/21/2011 | CN102188704A Methods of treating cancer using IL-21 and monoclonal antibody therapy |
| 09/21/2011 | CN102188703A Usage of yeast in preparation of anticoccidial drugs |
| 09/21/2011 | CN102188702A Compound immunological adjuvant of subunit vaccine for swine fever |
| 09/21/2011 | CN102188701A Aluminium phosphate adjuvant and preparation method thereof. |
| 09/21/2011 | CN102188700A Improved bacterial outer membrane vesicles |
| 09/21/2011 | CN102188449A Preparation method of high-immune whole-egg powder for resisting piglet diarrhea |
| 09/21/2011 | CN101724085B Method for purifying capsular polysaccharide |
| 09/21/2011 | CN101705233B Recombinant human herpes simplex virus I protein HSV I gG and application thereof |
| 09/21/2011 | CN101693747B Specific polysaccharide preparation process |
| 09/21/2011 | CN101491680B Infectious bursal disease live-vaccine heat-proof freeze-dry protectant and preparation method thereof |
| 09/21/2011 | CN101475639B Mixed yolk antibody for preventing and treating duck infectious serositis and preparation thereof |
| 09/21/2011 | CN101346137B Combination comprising combretastatin and anticancer agents |
| 09/21/2011 | CN101343250B Thrombopoietin mimetics |
| 09/21/2011 | CN101165068B Monoclonal antibody for resisting HER2/ErbB2 antigen, preparation method and medicament composition thereof |
| 09/20/2011 | US8022197 Nucleic acid and gene derived from novel HCV strain and replicon-replicating cell using said gene |
| 09/20/2011 | US8022190 An immunomolecule containing a soluble human Major Histocompatibility Complex class I effector domain linked to an antibody targeting domain; immunotherapy; anticarcinogenic agents |
| 09/20/2011 | US8022182 Truncated BAFF receptors |
| 09/20/2011 | US8022180 Method for preventing and treating Alzheimer's disease |
| 09/20/2011 | US8022179 Compositions and methods for topical application and transdermal delivery of an oligopeptide |
| 09/20/2011 | US8022174 C-type lectin transmembrane antigen expressed in human prostate cancer and uses therof |
| 09/20/2011 | US8022036 Use of thymosin alpha 1 for the treatment of immunological diseases |
| 09/20/2011 | US8021879 Adaptor protein that binds to mammalian toll-like receptor 3 and gene thereof |
| 09/20/2011 | US8021861 Pathogenic Escherichia coli associated protein |
| 09/20/2011 | US8021856 Transgenic cell for use as bioreactor in production of human estrogen receptor (HER) specific monoclonal antibody for use in targeted destruction of tumor cells |
| 09/20/2011 | US8021835 HCV coreceptor and methods of use thereof |
| 09/20/2011 | US8021834 Use of microparticles combined with submicron oil-in-water emulsions |
| 09/20/2011 | US8021833 Method for reducing HIV viral budding by administering a VPS28-specfic antibody that disrupts Gag-TSG101-VPS28 binding interactions |
| 09/20/2011 | US8021832 Proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines |
| 09/20/2011 | US8021673 Proteins with repetitive Bacterial-Ig-like (Big) domains present in Leptospira species |
| 09/20/2011 | US8021672 Development of a Chlamydia sp. vaccine strain |
| 09/20/2011 | US8021671 Pro-apoptotic bacterial vaccines to enhance cellular immune responses |
| 09/20/2011 | US8021670 Vaccine against Mycoplasma PRRSV |
| 09/20/2011 | US8021669 Methods for inducing an immune response in a host comprising administering modified vaccinia virus ankara (MVA) recombinants comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs) |
| 09/20/2011 | US8021668 Integrin alpha L I domain mutants with increased binding affinity |
| 09/20/2011 | US8021667 Compositions for immunotherapy and uses thereof |
| 09/20/2011 | US8021666 Administering antigen; anticancer agents; transfection human cells |